A real-world study based on the FAERS database evaluating adverse drug reactions in three amphotericin B lipid formulations
{{output}}
Background: Amphotericin B (AmB) remains the cornerstone in the treatment of severe fungal infections. However, selecting an appropriate lipid-based formulation for different clinical scenarios remains a challenge for clinicians ... ...
